Evidence map›Paper›PMID 31501502›Full record

ArticleScientific reports2019

A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector.

Junpei Ohtsuka, Masayuki Fukumura, Wakako Furuyama, Shujie Wang, Kenichiro Hara, Mitsuyo Maeda, Masato Tsurudome, Hiroko Miyamoto, Aika Kaito, Nobuyuki Tsuda and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Negative-Strand RNA Virus-Vectored Vaccines.Methods in molecular biology (Clifton, N.J.) · 2024
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Junpei OhtsukaDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan.
Masayuki FukumuraDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan. m-fukumura@biocomo.jp.
Wakako FuruyamaDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Shujie WangDepartment of Neural Regeneration and Cell Communication, Mie University Graduate School of Medicine, Tsu, Japan.
Kenichiro HaraDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan.
Mitsuyo MaedaMulti-Modal Microstructure Analysis Unit, RIKEN-JEOL Collaboration Center, Kobe, Japan.
Masato TsurudomeDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan.
Hiroko MiyamotoDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Aika KaitoDepartment of Neural Regeneration and Cell Communication, Mie University Graduate School of Medicine, Tsu, Japan.
Nobuyuki TsudaDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan.
Yosky KataokaMulti-Modal Microstructure Analysis Unit, RIKEN-JEOL Collaboration Center, Kobe, Japan.
Akira MizoguchiResearch Center for Development of Recombinant VLP Vaccines, Research Institutes of Excellence, Mie University, Tsu, Japan.
Ayato TakadaDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Tetsuya NosakaDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan. nosaka@doc.medic.mie-u.ac.jp.
Mie University · JPHokkaido University · JPJEOL (Japan) · JPChubu University · JPNational Institutes of Health · USThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ectopic protein with proper steric structure was efficiently loaded onto the envelope of the F gene-defective BC-PIV vector derived from human parainfluenza virus type 2 (hPIV2) by a reverse genetics method of recombinant virus production. Further, ectopic antigenic peptide was successfully loaded either outside, inside, or at both sides of the envelope of the vector. The BC-PIV vector harboring the Ebola virus GP gene was able to elicit neutralizing antibodies in mice. In addition, BC-PIV with antigenic epitopes of both melanoma gp100 and WT1 tumor antigen induced a CD8+ T-cell-mediated response in tumor-transplanted syngeneic mice. Considering the low pathogenicity and recurrent infections of parental hPIV2, BC-PIV can be used as a versatile vector with high safety for recombinant vaccine development, addressing unmet medical needs.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralChlorocebus aethiopsEpitopesGene OrderGenetic EngineeringGenetic VectorsHumansMiceNeutralization TestsParainfluenza Virus 2, HumanT-Lymphocyte SubsetsVaccines, SyntheticVaccinologyVero CellsAntibodies, NeutralizingAntibodies, ViralEpitopesVaccines, Synthetic

Identifiers

PMID31501502
PMCPMC6733870
OpenAlexW2972826013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.